Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
David R LallyAnat LoewensteinJennifer J ArnoldYit C YangKinfemichael GedifCatherine BestHersh PatelRamin TadayoniJeffrey S HeierPublished in: Eye (London, England) (2022)